RCG
ALXN

Ruggie Capital Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Ruggie Capital Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-28
Closed -$4K – 307
2019
Q2 		$4K Buy
+28
New +$3.61K 0.01% 186
2015
Q2 		– Sell
-19
Closed -$3K – 396
2015
Q1 		$3K Buy
+19
New +$3.44K ﹤0.01% 211

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ruggie Capital Group's ALXN Position: Q3 2019 in Review

Ruggie Capital Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2019, closing a stake of 28 shares — an estimated $4K sold.

Ruggie Capital Group first reported a position in ALXN in Q1 2015 and held it in 2 quarters. The position peaked at $4K in Q2 2019. 648 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

  • Ruggie Capital Group reported no remaining Alexion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Ruggie Capital Group sold 28 Alexion Pharmaceuticals shares in Q3 2019, an estimated $4K.
  • Ruggie Capital Group first reported a position in Alexion Pharmaceuticals in Q1 2015 and held it in 2 quarters.
  • Ruggie Capital Group's Alexion Pharmaceuticals position peaked at $4K in Q2 2019.
  • 648 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Ruggie Capital Group's 13F filing for Q3 2019, filed 6 Nov 2019.